Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus
| Autor: | Zemin Wan, Yajuan Zhu, Xianzhang Huang, Bin Wu, Zhuo Li, Lanhui She, Xinzhong Wu, Hongcan Liu, Qi-Zhen Zhuang, Peifeng Ke, Zhiliang Cai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
HBsAg
Mutant molecular mechanisms medicine.disease_cause Serology 03 medical and health sciences 0302 clinical medicine medicine chronic hepatitis B Pharmacology (medical) Original Research Pharmacology Hepatitis B virus Mutation lamivudine therapeutics business.industry lcsh:RM1-950 Lamivudine inflammation pharmacological reaction Virology YMDD mutation Reverse transcriptase biochemical response lcsh:Therapeutics. Pharmacology HBeAg 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Frontiers in Pharmacology Frontiers in Pharmacology, Vol 12 (2021) |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2021.648170 |
| Popis: | Background/Aims: Emergence of tyrosine-methionine-aspartate-aspartate (YMDD) motif in reverse transcriptase is a serious problem in chronic hepatitis B(CHB) patients after Lamivudine (LAM) therapy. However, the relationship between inflammation pharmacological reaction and YMDD mutational patterns of CHB has not been well-characterized. The aim of this study was to investigate the inflammation pharmacological reaction and different YMDD mutants patterns of CHB patients.Methods: We investigated the inflammation pharmacological reaction and YMDD mutational patterns through biochemical, serological and virological detection among 83 CHB patients, including 25 YMDD mutants, 25 under detection, and 33 control patients without YMDD mutants.Results: Prevalence of YMDD mutation patterns is different. Among 25 YMDD mutants patients, YIDD was the dominant mutation (72%), followed YVDD (16%) and the hybrid YIDD + YVDD (12%). The time course during the YMDD mutations was also different. 52.4% patients developed the mutation less than 12 months after the LAM therapy. Serum hepatitis B virus (HBV) DNA level in patients with YMDD mutants were significantly higher than that in control and negative groups. Serum HbsAg and HbeAg in patients with YMDD mutants were also higher than those in control and negative groups, despite no significant difference was found forserum HbeAb. ALT and AST levels were also significantly higher in mutants group.Conclusions: Illuminating inflammation pharmacological reaction and YMDD mutational patterns of CHB during pathological process may have implications for future therapy in YMDD mutation patients. This may have impact on the choice of treatment strategies for lamivudine-resistant HBV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|